Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Maura Pugliatti, Hans Peter Hartung, Celia Oreja-Guevara, Carlo Pozzilli, Laura Airas, Mona Alkhawajah, Nikolaos Grigoriadis, Melinda Magyari, Bart Van Wijmeersch, Magd Zakaria, Ralf Linker, Andrew Chan, Patrick Vermersch, Thomas Berger

Research output: Contribution to journalReview articlepeer-review


It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Original languageEnglish
Article number1045101
JournalFrontiers in Immunology
StatePublished - 17 Oct 2022
Externally publishedYes


  • adverse events
  • COVID-19
  • disease modifying therapies
  • immune response
  • multiple sclerosis
  • SARS-CoV-2
  • vaccines


Dive into the research topics of 'Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in'. Together they form a unique fingerprint.

Cite this